UroGen Pharma Ltd. (NASDAQ:URGN) Given Average Rating of “Buy” by Brokerages

UroGen Pharma Ltd. (NASDAQ:URGN) has received an average recommendation of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $38.20.

A number of research analysts recently weighed in on the company. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a report on Monday, March 10th. Finally, HC Wainwright decreased their target price on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th.

Insider Buying and Selling at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

A number of institutional investors have recently modified their holdings of the stock. Toronto Dominion Bank bought a new stake in shares of UroGen Pharma during the 4th quarter valued at $18,628,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of UroGen Pharma by 2.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after buying an additional 36,084 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after buying an additional 1,230,000 shares during the last quarter. Stonepine Capital Management LLC lifted its position in shares of UroGen Pharma by 15.7% during the 4th quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock worth $3,454,000 after buying an additional 43,979 shares during the last quarter. Finally, RTW Investments LP lifted its position in shares of UroGen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock worth $40,841,000 after buying an additional 47,447 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Stock Up 0.9 %

NASDAQ:URGN opened at $12.13 on Friday. The firm has a market capitalization of $559.12 million, a price-to-earnings ratio of -3.85 and a beta of 1.12. UroGen Pharma has a twelve month low of $9.03 and a twelve month high of $20.70. The stock’s 50 day moving average price is $10.54 and its two-hundred day moving average price is $11.57. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analysts’ expectations of $25.25 million. Equities research analysts expect that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.